

Sam Carr

Consultant

Email: sam.carr@oxera.com

Tel: +44 (0) 1865 253065

Languages: English



Expertise

- Antitrust
- Antitrust Damages
- Mergers

Sectors

- Pharmaceuticals and Life Sciences

Profile

Sam is a member of Oxera's Competition and Pharmaceuticals & Life Sciences teams. He has worked on a wide range of competition issues in a variety of sectors, including merger investigations by both the European Commission and the UK Competition and Markets Authority (CMA), follow-on antitrust damages, abuse of dominance cases, and market investigations. He also has experience of damages quantification in the pharmaceutical sector.

In 2021, Sam completed a six-month secondment as an economist at the CMA. During this time, he worked on merger investigations, including a large phase 2 merger in the transportation and storage industry.

Prior to joining Oxera, Sam completed a BSc and an MSc in Economics at the University of Warwick, focusing on econometrics and competition economics. Since joining, he has also completed an MSc in Economics at the University of Warwick.

Selected professional experience

- Supporting a global pharmaceutical supplier in its defence of a follow-on damages claim from a UK purchaser (2023–)
- Advising a biotechnology company in the context of merger investigations by the European Commission and other competition authorities globally (2023–)
- Advising a corporate veterinary group in relation to the CMA review into the veterinary services market (2023–)

- Assisting a supplier of demolition services in the UK with its appeal of a CMA Decision, focusing on market definition (2022–)
- Supported the Central Laser Facility to prepare the economic case for its successful application for funding from the UK government for a new laser (2022–23)
- Advised Mastercard in its defence of a damages claim from a group of UK retailers in relation to interchange fees (2021–22)
- Assessed the likelihood of competition concerns arising from a potential European merger in consumer goods (2020–21)
- Supported a purchaser of pharmaceuticals with quantifying the damages it is claiming from a supplier as a result of an unlawful injunction (2019–23)
- Assisted a network infrastructure provider in Eastern Europe in its response to a European Commission Article 101 investigation in relation to a network sharing agreement (2019–20)
- Advised a supplier of generic medicines in its response to allegations by the CMA of illegal market sharing in the market for a particular antibiotic in the UK (2019–20)
- Advising a North American consumer goods wholesaler in its defence against a collective claim for damages resulting from antitrust infringements (2018–)
- Advised a large financial institution in the context of an investigation by the European Commission into an alleged breach of Article 101 in the European Government Bonds market (2017–21)
- Undertaking econometric analysis for several purchasers of cathode ray tubes (CRTs) in relation to their follow-on damages claims against the global CRT cartel (2017–)
- Supported Bottomline, a financial services provider, in the successful clearance of its acquisition of Experian Payments Gateway by the CMA at phase 2 (2019–20)
- Assisted in preparing a report on behalf of the BGMA (an industry association) that assessed the functioning of the market for the supply of generic medicines in the UK (2018–19)
- Advised a generic pharmaceutical company in preparing a preliminary defence against likely allegations of excessive pricing and of engagement in anticompetitive agreements for a particular medicine in the UK (2018–19)
- Assisted a pharmaceutical company with its claim for damages resulting from unlawful regulation in the UK (2018–19)
- Supported Pfizer in Australia with quantifying the damages it owed to generic suppliers as a result of an unlawful injunction (2017–18)
- Assisted Fintrax, a financial services provider, with the successful clearance of its acquisition of GB TaxFree by the CMA (2017)
- Advised Liberty Global in the context of the successful clearance of its joint venture with Vodafone in the Netherlands by the European Commission (2016)
- Assisted with the preparation of the CMA study on the business rationales of using vertical restraints (2016)
- Advised a third party during the proposed merger between H3G and O2 being investigated by the European Commission (2015–16)
- Assisted Warner Bros in responding to a Statement of Objections from the European Commission regarding cross-border trade in audio-visual services (2015–16)
- Advised a UK distributor of memory products on a potential abuse of dominance claim regarding exclusivity agreements (2015–16)

- Assisted Scottish Power, a major UK energy supplier, in responding to the CMA's investigation into the GB energy market (2015–16)

Selected Publications

- Chowdhury, A., Barbera, A. and Carr, S. (2022), 'Biosimilar Competition: an Economist's Perspective', in I. Vandenborre et al. (eds), *The Guide to Life Sciences*, GCR, pp. 43–55.

Qualifications

- MSc Economics, University of Warwick, UK
- BSc (Hons) Economics, University of Warwick, UK